Endoglin in angiogenesis and vascular diseases
Top Cited Papers
- 19 February 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 11 (1), 79-89
- https://doi.org/10.1007/s10456-008-9101-9
Abstract
Endoglin is a transmembrane auxillary receptor for transforming growth factor-β (TGF-β) that is predominantly expressed on proliferating endothelial cells. Endoglin deficient mice die during midgestation due to cardiovascular defects. Mutations in endoglin and activin receptor-like kinase 1 (ALK1), an endothelial specific TGF-β type I receptor, have been linked to hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vascular dysplasia characterized by telangiectases and arteriovenous malformations. Endoglin heterozygote mice develop HHT-like vascular abnormalities, have impaired tumor and post-ischemic angiogenesis and demonstrate an endothelial nitric oxide synthase-dependent deterioration in the regulation of vascular tone. In pre-eclampsia, placenta-derived endoglin has been shown to be strongly upregulated and high levels of soluble endoglin are released into the circulation. Soluble endoglin was found to cooperate with a soluble form of vascular endothelial growth factor receptor 1 in the pathogenesis of pre-eclampsia by inducing endothelial cell dysfunction. Endoglin is highly expressed in tumor-associated endothelium, and endoglin antibodies have been successfully used to target activated endothelial cells and elicit anti-angiogenic effects in tumor mouse models. These exciting advances provide opportunities for the development of new therapies for diseases with vascular abnormalities.Keywords
This publication has 120 references indexed in Scilit:
- Endoglin is required for myogenic differentiation potential of neural crest stem cellsDevelopmental Biology, 2007
- Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathwayOncogene, 2007
- Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signalingProceedings of the National Academy of Sciences of the United States of America, 2007
- The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancerBritish Journal of Cancer, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Genotype-phenotype relationship in hereditary haemorrhagic telangiectasiaJournal of Medical Genetics, 2005
- Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted MiceScience, 2001
- Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglinEuropean Journal of Cancer, 2000
- Partnership between DPC4 and SMAD proteins in TGF-β signalling pathwaysNature, 1996
- Mechanism of activation of the TGF-β receptorNature, 1994